News Releases | Insmed Incorporated

Month Year

Email Alerts

Mar 22, 2010

Pharmaceutical Industry Veteran Nicholas LaBella Jr., MS, RPh, Joins Insmed as Chief Scientific Officer

Read more
Mar 15, 2010

Insmed Announces Fourth Quarter and Full-Year 2009 Financial Results

Read more
Mar 4, 2010

Insmed Regains NASDAQ Compliance

Read more
Mar 3, 2010

Insmed to Host Fourth Quarter and Full-Year 2009 Conference Call

Read more
Nov 6, 2009

Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2009

Read more
Oct 22, 2009

Insmed To Host Third Quarter 2009 Conference Call

Read more
Sep 16, 2009

Insmed Receives NASDAQ Deficiency Notice Relating to Minimum Bid Price

Read more
Aug 13, 2009

Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2009

Read more
Jul 31, 2009

Insmed to Host Second Quarter 2009 Conference Call

Read more
Jul 27, 2009

Insmed Provides Update on Supply of IPLEX(TM)

Read more
Jun 30, 2009

Insmed Announces Addition to the Russell 3000(R) Index

Read more
Jun 25, 2009

Insmed Announces Results of IPLEX(TM) Phase II Trial in Myotonic Muscular Dystrophy

Read more
Jun 15, 2009

Insmed CEO Resigns Due to Health Concerns

Read more
May 13, 2009

Insmed Announces First Quarter 2009 Financial Results

Read more
May 5, 2009

Insmed Regains NASDAQ Compliance

Read more
Apr 23, 2009

Insmed to Host First Quarter 2009 Conference Call

Read more
Apr 22, 2009

Insmed to Host First Quarter 2009 Conference Call

Read more
Mar 31, 2009

Insmed Completes Sale of Follow-On Biologics Platform to Merck & Co., Inc. for Gross Proceeds of $130 Million

Read more
Mar 30, 2009

Insmed Announces Agreement With IDIS to Manage Expanded Access Programs for IPLEX(TM)

Read more
Mar 25, 2009

Insmed Announces That NASDAQ Further Extends Temporary Suspension of Minimum Bid Closing Price Rule

Read more
Mar 11, 2009

Insmed Announces Fourth Quarter and Full-Year 2008 Financial Results

Read more
Mar 10, 2009

Insmed Announces FDA Issues Statement Regarding Position on Allowing Patients With ALS Access to IPLEX(TM) Under an IND

Read more
Feb 26, 2009

Insmed to Host Fourth Quarter and Full-Year 2008 Conference Call

Read more
Feb 12, 2009

Insmed Sells Follow-on Biologics Platform to Merck & Co., Inc. for Gross Proceeds of $130 Million

Read more
Jan 21, 2009

Insmed and Premacure Announce European Orphan Designation for IPLEX(TM) in Retinopathy of Prematurity in Infants

Read more
Dec 26, 2008

Insmed to Appeal Delisting Notification From Nasdaq

Read more
Dec 23, 2008

Insmed Announces that NASDAQ Extends Temporary Suspension of Minimum Bid Closing Price Rule

Read more
Nov 25, 2008

Insmed to Present at Sanford C. Bernstein Biosimilars Long View Conference

Read more
Nov 18, 2008

Insmed to Participate in Federal Trade Commission Roundtable on Follow-on Biologic Drugs: Framework for Competition and Continued Innovation

Read more
Nov 10, 2008

Insmed Gains Royalty-Free Worldwide Rights for IPLEX(TM) in Connection with Potential Expanded Access ALS Programs

Read more
Nov 5, 2008

Insmed to Present at Upcoming Healthcare Conferences

Read more
Oct 30, 2008

Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2008

Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2008
- Photos 4
Read more
Oct 22, 2008

NASDAQ's Temporary Suspension of Minimum Bid Closing Price Rules Extends Insmed's Compliance Date to March 20, 2009

Read more
Oct 21, 2008

Insmed Announces That NASDAQ Temporarily Suspends Minimum Bid Closing Price Rule

Read more
Oct 20, 2008

Insmed to Host Third Quarter 2008 Conference Call

Read more
Oct 14, 2008

Insmed Initiates Clinical Study for Follow-on Biologic Version of Neulasta(R)

Read more
Oct 14, 2008

Insmed to Seek Shareholder Approval for Reverse Split

Read more
Sep 23, 2008

Insmed and Premacure Cite Study Results Demonstrating Potential Effectiveness of IPLEX(TM) in Preventing Blindness in Premature Infants

Read more
Sep 15, 2008

Insmed to Present at Biosimilars 2008 Conference

Read more
Sep 4, 2008

Insmed to Present at BioPharm Asia 2008 Conference

Read more
Sep 3, 2008

NASDAQ Hearing Panel Grants Insmed Request for Continued Listing on the NASDAQ Stock Market

Read more
Aug 8, 2008

Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2008

Read more
Jul 28, 2008

Jim Miller, Ph.D. Joins Insmed Therapeutic Proteins as Vice President of Process Development

Read more
Jul 25, 2008

Insmed to Host Second Quarter 2008 Conference Call

Read more
Jul 25, 2008

Insmed CEO to Present at Drug Discovery & Development Conference

Read more
Jul 22, 2008

Insmed CEO to Present at Congressional Briefing on Follow-On Biologics

Read more
Jul 21, 2008

Insmed Provides Update on IPLEX(TM) Programs

Read more
Jul 17, 2008

Insmed Partners With Bill Thomas, Former House Ways and Means Chairman, as Strategic Advisor

Read more
Jul 14, 2008

Insmed Retains RBC Capital Markets as Strategic Financial Advisor

Read more
Jul 10, 2008

Insmed Announces First Human Bioequivalence Data for a Follow-on Biologic by a U.S. Company

Read more
Jul 9, 2008

Insmed to Present at Collins Stewart Fourth Annual Growth Conference

Read more
Jun 20, 2008

Insmed to Request Hearing Before NASDAQ Panel to Review NASDAQ Staff Determination

Read more
May 8, 2008

Insmed Announces First Quarter 2008 Financial Results

Read more
May 8, 2008

/C O R R E C T I O N -- Insmed Inc./

Read more
Apr 29, 2008

Insmed Provides Update on Follow-On Biologics and IPLEX(TM) Programs

Read more
Apr 24, 2008

Insmed to Host First Quarter 2008 Conference Call

Read more
Apr 22, 2008

Insmed to Present at CBI Follow-On Biologics Conference

Read more
Apr 16, 2008

Insmed Initiates Clinical Study for Follow-on Biologic Version of Neupogen(R)

Read more
Apr 10, 2008

Insmed Selected to Complete Congressional Questionnaire Regarding the Potential Establishment of a Follow-On Biologics Regulatory Pathway

Read more
Mar 8, 2008

Insmed Announces Additional Information in Compliance With NASDAQ Rules

Read more
Mar 4, 2008

Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results

Read more
Feb 28, 2008

Insmed Announces Listing Transfer from Nasdaq Global Market to Nasdaq Capital Market

Read more
Feb 19, 2008

Insmed to Host Fourth Quarter and Full-Year 2007 Conference Call

Read more
Feb 11, 2008

Study by Leading Economist Identifies Potential for $378 Billion of Savings From Follow On Biologics

Read more
Feb 5, 2008

Insmed Launches National Awareness Campaign Surrounding Follow-On Biologics

Read more
Feb 5, 2008

Insmed CEO Issues Statement on White House FY09 Budget and FDA Statements on Follow-On Biologics

Read more
Jan 28, 2008

Insmed Provides Update on IPLEX(TM) Expanded Access Program in Italy for the Treatment of Amyotrophic Lateral Sclerosis

Read more
Jan 22, 2008

Insmed Completes External Assessment of Myotonic Muscular Dystrophy Market

Read more
Dec 18, 2007

Insmed Receives FDA Orphan Drug Designation for IPLEX(TM) in the Treatment of Myotonic Muscular Dystrophy

Read more
Dec 12, 2007

Insmed Awarded $2.1 Million by Muscular Dystrophy Association

Read more
Dec 6, 2007

Insmed to Present at the IBC 5th Annual Global Follow-On Biologics Conference

Read more
Dec 6, 2007

Insmed Appoints Dennis M. Lanfear to Board Of Directors

Read more
Dec 3, 2007

Insmed Retains FD and Gibraltar Associates for Investor Relations and Corporate Communications

Read more
Nov 13, 2007

Insmed Advances Follow on Biologics Initiative

Read more
Nov 8, 2007

Insmed Reports Financial Results for Third Quarter and Nine Months Ended September 30, 2007

Read more
Nov 5, 2007

Insmed Announces Initiation of Phase II Clinical Trial with IPLEX(TM) in Myotonic Muscular Dystrophy

Read more
Oct 24, 2007

Insmed Announces Third Quarter Earnings Release Date and Conference Call

Read more
Oct 23, 2007

Insmed to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference

Read more
Oct 3, 2007

Insmed to Present at the 2007 BIO Investor Forum on Wednesday, October 10, 2007

Read more
Aug 2, 2007

Insmed Reports Financial Results for Second Quarter and First Half of 2007

Read more
Jul 25, 2007

Insmed Announces Second Quarter and First Half Earnings Release Date and Conference Call

Read more
Jul 9, 2007

Insmed Inc. to Present at C.E. Unterberg, Towbin Growth Conference

Read more
Jun 26, 2007

Insmed Inc. Welcomes Studies Linking IGFBP-3 to Prevention of Blindness in Premature Infants

Read more
Jun 25, 2007

Experienced Biopharmaceutical Executive Steve Glover Joins Insmed; Will Lead Development of Follow-on Biologics

Read more
Jun 19, 2007

Insmed Receives NASDAQ Deficiency Notice Relating to Minimum Bid Price

Read more
May 10, 2007

Insmed Incorporated Reports Financial Results for First Quarter Ended March 31, 2007

Read more
May 7, 2007

Insmed Announces First Quarter Earnings Release Date and Conference Call

Read more
May 4, 2007

Insmed Raises Approximately $18.2 Million in Registered Direct Offering

Read more
May 3, 2007

Insmed Announces Promising Results From IPLEX Phase II Myotonic Muscular Dystrophy Clinical Study

Read more
May 2, 2007

Insmed CEO Geoffrey Allan Testifies at Energy and Commerce Committee Hearing

Read more
Apr 30, 2007

Insmed Releases Positive Results from IPLEX Phase II HIV-Associated Adipose Redistribution Syndrome Clinical Study

Read more
Apr 25, 2007

Insmed Inc. Releases Investor Fact Sheet with Updates on Drug Development Progress

Read more
Mar 26, 2007

Insmed CEO Geoffrey Allan Testifies at Congressional Hearing

Read more
Mar 16, 2007

Insmed Announces Additional Information In Compliance With NASDAQ Rules

Read more
Mar 15, 2007

Insmed Inc. Reports Financial Results for Fourth Quarter and Twelve Months

Read more
Mar 10, 2007

Update: Insmed to Hold 2006 Q4 and Year End Earnings Results

Read more
Mar 9, 2007

Insmed to Hold 2006 Q4 and Year End Earnings Results

Read more
Mar 7, 2007

Insmed Announces Restructure, Settlement Ending IPLEX(TM) Patent Dispute

Read more
Mar 6, 2007

Insmed to Discuss Litigation Settlement with Tercica

Read more
Jan 10, 2007

Italian Ministry of Health Requests IPLEX(TM) for Treatment of ALS (Lou Gehrig's Disease)

Read more

Show per page

Stay In The Loop

Want to stay up to date on our news, events, and filings? Set up your email alerts.

Investor Presentation

View the latest Insmed Investor Presentation

Download

Company

Our Global Company

Patients

Current Clinical Trials

Science

Therapies

Responsibility

Responsibility in Action

Press Releases

Company

Our Global Company

Patients

Current Clinical Trials

Science

Therapies

Responsibility

Responsibility in Action

Footer